Study
| Single-arm, Phase-3 trial (SONAYA) |
| Platinum-resistant epithelial ovarian cancer (up to three prior lines of systemic therapy; all patients were required to have received bevacizumab) |
| Mirvetuximab soravtansine at 6 mg/kg every 3 weeks (n=104) |
Efficacy
| ORR: 31.7% [22.9 – 41.6] |
| mDoR: 6.9 mos [5.6 – 9.7 mos] |
Safety
| Adverse reactions 20%: vision impairment, keratopathy, peripheral neuropathy, ALT and AST increased |
Article not yet published
http://www.ncbi.nlm.nih.gov/pubmed/0
Reviewed by Elvin Chalabiyev, MD on Jan 10, 2023
